Tier 2 — strong

Bioavailabilities of quercetin-3-glucoside and quercetin-4'-glucoside do not differ in humans

M R Olthof, P C Hollman, T B Vree, M B Katan
The Journal of nutrition 2000 130(5):1200

Bibliography

PubMed
PMID 10801919
DOI
10.1093/jn/130.5.1200
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignHuman crossover glucoside absorption comparison
ModelHuman intervention research
Sample9 healthy adults
InterventionQuercetin-3-glucoside 325 micromol versus quercetin-4-glucoside 331 micromol
DurationSingle-dose comparisons
EndpointsExposure and pharmacokinetics

What the study showed, in plain terms

Published in 2000, this source examined forms, absorption and food sources. Design: Human crossover glucoside absorption comparison. Sample/model: 9 healthy adults. The exposure or intervention was Quercetin-3-glucoside 325 micromol versus quercetin-4-glucoside 331 micromol. Follow-up or treatment period: Single-dose comparisons.

The two glucosides had similar bioavailability and rapid peak concentrations.

Small acute pharmacokinetic study. Similar exposure between these glucosides does not establish equivalent clinical benefits across all quercetin forms.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin Forms: Dihydrate, Phytosome, Liposomal and Glycosides. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • The two glucosides had similar bioavailability and rapid peak concentrations.
  • The recorded outcome domains were Exposure and pharmacokinetics.
  • The result applies to the tested exposure: Quercetin-3-glucoside 325 micromol versus quercetin-4-glucoside 331 micromol; Single-dose comparisons.

What this study can and cannot tell us

  • Small acute pharmacokinetic study. Similar exposure between these glucosides does not establish equivalent clinical benefits across all quercetin forms.
  • A change in blood exposure or a metabolic marker is not a demonstrated improvement in symptoms, disease events or lifespan. The tested formulation and co-administered medicines matter.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Improving quercetin bioavailability: A systematic review and meta-analysis of human intervention studies
Lu Liu et al. · Food chemistry · 2025
Tier 2
Microbiological and Pharmacokinetic Aspects of a Water-Soluble Quercetin 3-O-rutinoside, EubioQuercetin: A Direct Comparison With Quercetin in In Vitro and Human Clinical Studies
Naoto Yamaguchi et al. · Journal of food science · 2025
Tier 2
Comparative Pharmacokinetics and Safety of a Micellar Chrysin-Quercetin-Rutin Formulation: A Randomized Crossover Trial
Afoke Ibi et al. · Antioxidants (Basel, Switzerland) · 2025
Tier 2
Enhanced Bioavailability and Pharmacokinetics of a Natural Self-Emulsifying Reversible Hybrid-Hydrogel System of Quercetin: A Randomized Double-Blinded Comparative Crossover Study
Ashil Joseph et al. · ACS omega · 2022

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology